For the year ending 2025-12-31, KPTI made $146,067K in revenue. -$196,039K in net income. Net profit margin of -134.21%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue from contract with customer, license and other revenue | 146,067 | |||
| Cost of sales-Product | 5,949 | |||
| Research and development | 125,617 | |||
| Selling, general and administrative | 105,208 | |||
| Total operating expenses | 236,774 | |||
| Loss from operations | -90,707 | |||
| Interest income | 2,773 | |||
| Interest expense | 45,849 | |||
| (loss) gain on extinguishment of debt | -62,365 | |||
| Other income (expense), net | 152 | |||
| Total other (expense) income, net | -105,289 | |||
| Loss before income taxes | -195,996 | |||
| Income tax provision | 43 | |||
| Net loss | -196,039 | |||
| Earnings per share, basic, total | -17.93 | |||
| Earnings per share, diluted, total | -17.93 | |||
| Weighted average number of shares outstanding, basic, total | 10,935 | |||
| Weighted average number of shares outstanding, diluted | 10,935 | |||
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)